Search results
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
The following questions are often asked by people contacting Retina UK.
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
Retina UK is a charity supporting people affected by inherited sight loss and investing in medical research to help make their challenges a thing of the past.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Dr Daniel Jackson discusses what images you are likely to have during a hospital appointment; how they are taken; why we take them; how we interpret them; and how this helps in the management and treatment of retinal conditions
